Brian Marckx, CFA
Long/short equity

iCAD Inc: Expect 2013 Revenue Momentum To Carry Through 2014

iCAD Inc. (NASDAQ:ICAD) announced financial results for the fourth quarter and year ending December 31st. Revenue growth momentum continues as does improvement in operating income. Revenue and operating income for both Q4 and the full-year were the highest for each respective period since 2008. This is the highest since acquiring Xoft in December 2010. The Xoft acquisition brought with it the Axxent System, an electronic brachytherapy device used for the treatment of cancer. The initial target market was for intraoperative radiation therapy (IORT) for breast cancer but use for non-melanoma skin cancer has quickly become the driving force behind ICAD's recently ramping revenues.

Much of the growth continues to come from the Cancer Therapy business and, in particular,

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details